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Background: There is growing evidence for Trans-catheter Aortic Valve Implantation (TAVI) in the high-risk population with severe symptomatic 
aortic stenosis; the majority of which is derived from early clinical outcome data with little in the way of long-term follow up. We aim to present long-
term outcome data at 4-year follow-up in patients who underwent TAVI procedure in the United Kingdom (UK). 
Method: We extracted data from the UK TAVI Registry incorporating a combined dataset from two UK institutions. This was an all-inclusive 
prospective data collection, irrespective of access site, valve selection or technology. The data was collected in 36 patients who underwent 36 TAVI 
procedures up to and including November 2007. Mortality tracking was achieved in 100% of patients. 
Results: 36 patients had an average age of 85±5.2 years, 18/36 (50%) were male, with peak aortic valve gradient: 77±25 mmHg and an average 
logistic EuroScore of 24.7±15.0. 6/36 (16.7%) had undergone previous cardiac surgery with 15/36 (41.7%) having pre-existing coronary artery 
disease. Survival at 30 days was 92.7%, 64% at 1 year, and 44% at 4-year follow-up with no significant functional prosthesis deterioration in these 
patients. 
Conclusions: TAVI outcomes data yields positive results with 44% 4 year survival, however with a marked decline in survival in the first year.
Figure 1. Baseline Characteristics and Survival 
Variable N=36
Age (years) 85±5.2
Sex (male) 18/36 (50%)
Peak Aortic Valve gradient (mmHg) 77±25
NYHA II-IV (2.4±0.5)
Log. EuroScore 24.7±15.0
Coronary Artery Disease 15/36 (41.7%)
Previous Cardiac Surgery 6/36 (16.7%)
Survival:
30 days 33/36 (92.7%)
1 year 23/36 (64%)
2 years 22/36 (61.2%)
4 years/total 16/36 (44%)
Values: n/N (%), mean±sd
